Salarius Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Salarius Pharmaceuticals
SLRX Stock  USD 0.86  0.05  5.49%   
Salarius Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Salarius Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Salarius Pharmaceuticals financial statements helps investors assess Salarius Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Salarius Pharmaceuticals' valuation are summarized below:
Gross Profit
-15.8 M
Market Capitalization
1.4 M
Enterprise Value Revenue
0.1368
Earnings Share
(5.14)
Quarterly Revenue Growth
(1.00)
We have found one hundred twenty available fundamental trend indicators for Salarius Pharmaceuticals, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Salarius Pharmaceuticals current market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road.

Salarius Pharmaceuticals Total Revenue

0.0

Check Salarius Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Salarius Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 441.7 K, Depreciation And Amortization of 8.6 K or Interest Expense of 281.6 K, as well as many indicators such as Price To Sales Ratio of 97.37, Dividend Yield of 0.0011 or PTB Ratio of 3.51. Salarius financial statements analysis is a perfect complement when working with Salarius Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Salarius Pharmaceuticals Correlation against competitors.
For more information on how to buy Salarius Stock please use our How to Invest in Salarius Pharmaceuticals guide.

Salarius Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets5.6 M5.9 M30.9 M
Slightly volatile
Other Current Liabilities532.5 K366.1 K594.3 K
Very volatile
Total Current Liabilities2.3 M1.2 M2.2 M
Pretty Stable
Property Plant And Equipment Net6.7 K7.1 K115.8 K
Slightly volatile
Accounts Payable515.4 K542.6 K1.8 M
Very volatile
Cash5 M5.3 M22.5 M
Slightly volatile
Non Current Assets Total73 K76.9 K2.4 M
Pretty Stable
Cash And Short Term Investments5 M5.3 M27.5 M
Slightly volatile
Common Stock Total Equity1.6 K2.7 K1.4 K
Slightly volatile
Liabilities And Stockholders Equity5.6 M5.9 M30.9 M
Slightly volatile
Non Current Liabilities Total347.8 K366.1 K13.2 M
Slightly volatile
Other Current Assets816.3 K712.7 K651.9 K
Slightly volatile
Other Stockholder Equity82 M93.9 M57.9 M
Slightly volatile
Total Liabilities1.1 M1.2 M15 M
Slightly volatile
Property Plant And Equipment Gross19.4 K20.4 K120.3 K
Slightly volatile
Total Current Assets5.6 M5.9 M28.5 M
Slightly volatile
Common Stock4294521 K
Pretty Stable
Common Stock Shares Outstanding3.9 M3.8 M981.9 K
Slightly volatile
Capital Surpluse35.6 M37.4 M91 M
Slightly volatile
Deferred Long Term Liabilities11.7 K13.1 K14.3 K
Slightly volatile
Property Plant Equipment6.7 K7.1 K158.1 K
Slightly volatile
Current Deferred Revenue298.3 K440.6 K252.7 K
Slightly volatile
Net Receivables1.2 M1.9 M981.8 K
Slightly volatile
Intangible Assets10.7 M10.2 M4.1 M
Slightly volatile
Net Invested Capital4.8 M5 M21.3 M
Slightly volatile
Net Working Capital4.5 M4.7 M19.1 M
Slightly volatile
Capital Stock3363541.6 K
Slightly volatile
Short and Long Term Debt Total338.4 K260.7 K435.5 K
Slightly volatile
Short and Long Term Debt338.4 K260.7 K435.5 K
Slightly volatile
Short Term Debt338.4 K260.7 K435.5 K
Slightly volatile

Salarius Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income441.7 K409.2 K278.7 K
Slightly volatile
Depreciation And Amortization8.6 K9 K83 K
Pretty Stable
Selling General Administrative4.9 K5.1 K10.9 M
Slightly volatile
Other Operating Expenses11 K11.6 K21.1 M
Slightly volatile
Research Development6.1 K6.5 K10.1 M
Slightly volatile
Total Operating Expenses11 K11.6 K21 M
Slightly volatile
Non Operating Income Net Other667.5 K502.7 K537.3 K
Slightly volatile
Total Other Income Expense Net301317288.8 K
Very volatile
Discontinued Operations1.5 K1.6 K1.8 K
Slightly volatile
Cost Of Revenue8.6 K9 K352.7 K
Slightly volatile
Reconciled Depreciation9.1 K9.6 K189.1 K
Slightly volatile
Extraordinary Items1.5 K1.6 K1.8 K
Slightly volatile
Selling And Marketing Expenses4.6 M5.1 M5.6 M
Slightly volatile

Salarius Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation448.7 K472.4 K3.5 M
Slightly volatile
Begin Period Cash Flow18.2 M10.9 M25.2 M
Slightly volatile
Depreciation8.6 K9 K83 K
Pretty Stable
Total Cash From Financing Activities5.7 M6 M34.7 M
Slightly volatile
End Period Cash Flow5 M5.3 M32.8 M
Slightly volatile
Issuance Of Capital Stock10.1 M8 M4.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio97.37102356
Slightly volatile
Dividend Yield0.00110.00120.0013
Slightly volatile
PTB Ratio3.513.699.7382
Slightly volatile
Days Sales Outstanding254242117
Slightly volatile
Book Value Per Share1.771.861.8 K
Slightly volatile
Average Payables1 M1.6 M1.2 M
Slightly volatile
Stock Based Compensation To Revenue0.330.353.3127
Slightly volatile
Capex To Depreciation3.0E-43.0E-430.2534
Slightly volatile
PB Ratio3.513.699.7382
Slightly volatile
EV To Sales80.0284.24339
Slightly volatile
Payables Turnover0.01820.01920.1552
Very volatile
Sales General And Administrative To Revenue1.522.991.7032
Slightly volatile
Research And Ddevelopement To Revenue10.055.3412.5273
Slightly volatile
Capex To Revenue5.0E-46.0E-40.2479
Slightly volatile
Cash Per Share1.972.081.8 K
Slightly volatile
Days Payables Outstanding18.7 K19.7 K34.2 K
Slightly volatile
Income Quality0.780.920.8823
Slightly volatile
Intangibles To Total Assets0.190.20.1676
Slightly volatile
Net Debt To EBITDA41139278.667
Slightly volatile
Current Ratio5.485.7717.3601
Slightly volatile
Tangible Book Value Per Share1.771.861.8 K
Slightly volatile
Receivables Turnover1.481.5649.8688
Slightly volatile
Shareholders Equity Per Share1.771.861.8 K
Slightly volatile
Debt To Equity0.0330.04930.0464
Pretty Stable
Capex Per Share0.00.06.1283
Slightly volatile
Graham Net Net1.541.621.7 K
Slightly volatile
Average Receivables6.1 K5.7 K5.6 K
Slightly volatile
Revenue Per Share1.221.2824.2774
Slightly volatile
Interest Debt Per Share0.09690.12.4784
Slightly volatile
Debt To Assets0.02650.03960.0362
Very volatile
Price Book Value Ratio3.513.699.7382
Slightly volatile
Days Of Payables Outstanding18.7 K19.7 K34.2 K
Slightly volatile
Ebt Per Ebit1.061.120.9857
Very volatile
Total Debt To Capitalization0.03150.04670.0443
Pretty Stable
Debt Equity Ratio0.0330.04930.0464
Pretty Stable
Quick Ratio5.485.7717.3613
Slightly volatile
Net Income Per E B T0.750.890.8544
Slightly volatile
Cash Ratio4.965.2215.5106
Slightly volatile
Days Of Sales Outstanding254242117
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.820.981.0097
Pretty Stable
Price To Book Ratio3.513.699.7382
Slightly volatile
Fixed Asset Turnover22121095.5651
Slightly volatile
Debt Ratio0.02650.03960.0362
Very volatile
Price Sales Ratio97.37102356
Slightly volatile
Asset Turnover0.03850.04060.0564
Slightly volatile
Gross Profit Margin0.590.890.6215
Slightly volatile
Price Fair Value3.513.699.7382
Slightly volatile

Salarius Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap28.4 M29.9 M129.9 M
Slightly volatile
Enterprise Value15.2 M16 M104.8 M
Slightly volatile

Salarius Fundamental Market Drivers

Cash And Short Term Investments5.9 M

Salarius Upcoming Events

25th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
25th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Salarius Pharmaceuticals Financial Statements

Salarius Pharmaceuticals investors use historical fundamental indicators, such as Salarius Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Salarius Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue440.6 K298.3 K
Cost Of Revenue9 K8.6 K
Stock Based Compensation To Revenue 0.35  0.33 
Sales General And Administrative To Revenue 2.99  1.52 
Research And Ddevelopement To Revenue 5.34  10.05 
Revenue Per Share 1.28  1.22 
Ebit Per Revenue(6.27)(6.58)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce

Additional Tools for Salarius Stock Analysis

When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY